Coloplast Q2 Profit Misses on Kerecis Impairment

Core Summary

Danish medical device firm Coloplast A/S reported second-quarter earnings that missed analyst expectations, driven by a significant DKK 3 billion impairment charge against its Kerecis wound-treatment unit. The company also issued a full-year outlook below consensus, citing sales disruptions and currency headwinds.

Performance Overview

For the second quarter ending March 31, Coloplast posted an EBIT before special items of DKK 1.82 billion, falling short of the DKK 1.89 billion consensus. Organic revenue growth was 6%, slightly below the median estimate of 6.5%. The Kerecis division recorded 0% organic growth, which the company attributed to significant sales disruption from a Medicare reimbursement change in the U.S. outpatient market.

Financial Impact and Outlook

Coloplast has adjusted its full-year guidance for 2025-26. It now expects organic revenue growth of 5% to 6%, below the 6.7% analyst consensus. Full-year EBIT growth in constant currencies is projected at around 5%, also missing the 6% median forecast. The negative impact from currencies is expected to be 2 to 3 percentage points on reported revenue growth. Despite the challenges, the company announced an interim dividend of DKK 5 per share.

Summary and Outlook

The impairment of the Kerecis unit has materially impacted Coloplast's financial results and outlook. Market recovery in the U.S. outpatient setting and the company's ability to manage currency fluctuations will be key factors for investors to monitor in the upcoming quarters.

FAQ

Q: Why did Coloplast report a DKK 3 billion impairment loss?
A: The impairment was recognized against the Kerecis unit's goodwill after it recorded 0% organic growth due to disruptions from a Medicare reimbursement policy change.

Q: What was Coloplast's EBIT for the second quarter?
A: The company reported a Q2 EBIT before special items of DKK 1.82 billion, missing the analyst consensus of DKK 1.89 billion.

Q: What is Coloplast's revenue growth guidance for the full year?
A: Coloplast projects full-year organic revenue growth between 5% and 6%, which is below the market consensus of 6.7%.

Source: Investing.com